Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock Holdings Lifted by Janus Henderson Group PLC

Janus Henderson Group PLC raised its stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 74.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,558,519 shares of the company's stock after purchasing an additional 1,951,220 shares during the period. Janus Henderson Group PLC owned 4.81% of Edgewise Therapeutics worth $121,616,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of EWTX. California State Teachers Retirement System increased its position in Edgewise Therapeutics by 23.1% during the first quarter. California State Teachers Retirement System now owns 36,467 shares of the company's stock worth $665,000 after purchasing an additional 6,847 shares during the last quarter. Simplicity Wealth LLC acquired a new position in Edgewise Therapeutics during the second quarter worth approximately $274,000. SG Americas Securities LLC increased its position in Edgewise Therapeutics by 657.9% during the second quarter. SG Americas Securities LLC now owns 64,173 shares of the company's stock worth $1,156,000 after purchasing an additional 55,706 shares during the last quarter. Bank of New York Mellon Corp increased its position in Edgewise Therapeutics by 26.6% during the second quarter. Bank of New York Mellon Corp now owns 268,712 shares of the company's stock worth $4,840,000 after purchasing an additional 56,447 shares during the last quarter. Finally, Rhumbline Advisers increased its position in Edgewise Therapeutics by 16.7% during the second quarter. Rhumbline Advisers now owns 98,269 shares of the company's stock worth $1,770,000 after purchasing an additional 14,041 shares during the last quarter.

Edgewise Therapeutics Stock Performance

Shares of EWTX stock traded down $0.49 on Thursday, hitting $31.57. The stock had a trading volume of 1,046,180 shares, compared to its average volume of 932,541. The firm has a market capitalization of $2.99 billion, a price-to-earnings ratio of -21.05 and a beta of 0.12. The stock's 50 day moving average is $32.26 and its 200-day moving average is $23.54. Edgewise Therapeutics, Inc. has a 52-week low of $6.44 and a 52-week high of $38.12.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.01. Equities analysts expect that Edgewise Therapeutics, Inc. will post -1.45 earnings per share for the current year.

Insider Buying and Selling at Edgewise Therapeutics

In other Edgewise Therapeutics news, insider Alan J. Russell sold 75,000 shares of the stock in a transaction on Friday, September 20th. The shares were sold at an average price of $28.27, for a total transaction of $2,120,250.00. Following the transaction, the insider now directly owns 12,719 shares in the company, valued at $359,566.13. This represents a 85.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO R Michael Carruthers sold 125,092 shares of the stock in a transaction on Friday, September 20th. The shares were sold at an average price of $28.57, for a total transaction of $3,573,878.44. Following the transaction, the chief financial officer now owns 6,904 shares in the company, valued at $197,247.28. This trade represents a 94.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 278,176 shares of company stock worth $7,893,316 in the last ninety days. 24.11% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on EWTX. JPMorgan Chase & Co. increased their price objective on shares of Edgewise Therapeutics from $30.00 to $31.00 and gave the stock an "overweight" rating in a research report on Monday, August 12th. Piper Sandler increased their price objective on shares of Edgewise Therapeutics from $48.00 to $51.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. Truist Financial increased their price objective on shares of Edgewise Therapeutics from $33.00 to $50.00 and gave the stock a "buy" rating in a research report on Wednesday, November 27th. Evercore ISI began coverage on shares of Edgewise Therapeutics in a research report on Friday, November 22nd. They issued an "outperform" rating and a $45.00 price objective for the company. Finally, Wedbush increased their price objective on shares of Edgewise Therapeutics from $44.00 to $45.00 and gave the stock an "outperform" rating in a research report on Friday, November 8th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Edgewise Therapeutics has an average rating of "Buy" and an average price target of $42.33.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.